SUSVIMO®(ranibizumab injection)

Your go-to destination for the latest advancements in ophthalmology. Follow us to see how SUSVIMO is redefining the possibilities for patients living with nAMD, DME or DR. Visit https://www.susvimo-hcp.com/ for more information Intended for US healthcare professionals only. SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR) who have previously responded to at least 2 intravitreal injections of a vascular endothelial growth factor (VEGF) inhibitor. Important Safety Information WARNING: ENDOPHTHALMITIS 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ran Community Guidelines: All content posted to the SUSVIMO page will be moderated. We reserve the right to not post or remove any comments, posts, or questions that do not meet our community guidelines, or are offensive, threatening, or otherwise inappropriate. Except SUSVIMO, do not mention or discuss any other medicines by name—Genentech’s or anyone else’s. Please do not post any comments that reference additional pharmaceutical brands, including specific medicines, products, or services. Reporting side effects is very important; if you know or experience any side effects, we encourage you to report it immediately to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription products directly to the FDA at 1-800-FDA-1088 or by visiting www.fda.gov/medwatch. Information provided on this page is for informational purposes only, and is not intended to replace the advice or clinical judgment of any qualified medical professional. Genentech does not control and is not responsible for the accuracy of any opinions, advice, information, or other comments posted on this page by third parties. ©2025 Genentech USA, Inc. M-US-00026131(v2.0) 07/25